BioSyent (CVE:RX) Director Stephen Edwin William Wilton Sells 805 Shares

BioSyent Inc. (CVE:RX) Director Stephen Edwin William Wilton sold 805 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of C$15.84, for a total value of C$12,751.20. Following the completion of the transaction, the director directly owned 7,876 shares in the company, valued at approximately C$124,755.84. This represents a 9.27% decrease in their ownership of the stock.

BioSyent Price Performance

CVE RX opened at C$15.75 on Friday. The business’s fifty day moving average is C$14.77 and its 200 day moving average is C$14.72. BioSyent Inc. has a fifty-two week low of C$10.65 and a fifty-two week high of C$16.00. The company has a debt-to-equity ratio of 6.85, a quick ratio of 6.91 and a current ratio of 2.07. The company has a market capitalization of C$178.18 million, a PE ratio of 18.44 and a beta of 1.00.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.